Latest eBooks

The term proteomics – used to describe the large-scale characterization of proteins – was coined in the 1990s by Mark Wilkins, who was a PhD student at the time. Download this eBook to learn more about recent developments in proteomics research.

This e-book is a compelling introduction to HYPER technology and the impact it has had as an industry standard on a variety of adherent cell expansion applications, including viral vector manufacturing and stem cell expansion.

Download this eBook to discover factors influencing a ligand or catalyst's suitability for production, prominent classes of adamantyl-based phosphine ligands and much more.

The use of organoids, self-organized three-dimensional (3D) assemblies of cells, as research tools has become more common due to their ability to better recapitulate human disease compared to more traditional models.

By recreating many of the cell-cell and cell-matrix interactions found in native tissues, spheroids and organoids provide more physiologically accurate models of disease and development than traditional 2D cultures.

Binding kinetic research is both beneficial and critical for successful drug discovery research. In this eBook, we delve into the role of binding kinetics in pharmacology, methods for measuring kinetic parameters, and applications.

Every field of biology has a moonshot vision. Whether that be identifying a new cell type in a poorly characterized tissue, finding a lasting, effective drug target for Alzheimer’s disease or reaching 100% remission rates for immunotherapy across patients and cancer types.

Ultimately, good quality results rely on lab equipment being efficient at what they do but with constant developments of new technologies, changing regulations and standards, it’s often overwhelming to keep pace.

Download this eBook to learn how modern flow cytometers are advances enabling advances in fields such as molecular biology, immunology, environmental science and pathology.

Mycoplasma contamination of manufacturing cell cultures is rare, but presents a threat for biologics manufacturers. Traditionally, testing was done using a culture-based, 28-day mycoplasma test. More recently, PCR-based alternatives have evolved, driven by an industry move to shorten lot disposition cycles and the emergence of cell-based therapeutics that require a more rapid test.